loading
Bicycle Therapeutics Plc Adr stock is traded at $7.29, with a volume of 235.26K. It is down -9.42% in the last 24 hours and down -12.66% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$8.07
Open:
$8.04
24h Volume:
235.26K
Relative Volume:
0.86
Market Cap:
$363.04M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.2158
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
-9.98%
1M Performance:
-12.66%
6M Performance:
-21.40%
1Y Performance:
-67.81%
1-Day Range:
Value
$7.26
$8.11
1-Week Range:
Value
$7.26
$9.08
52-Week Range:
Value
$6.10
$25.39

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Name
Bicycle Therapeutics Plc Adr
Name
Phone
011441223261503
Name
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Employee
305
Name
Twitter
@Bicycle_tx
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
BCYC's Discussions on Twitter

Compare BCYC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
7.29 559.80M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.52 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.42 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
432.26 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
822.85 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
183.87 40.44B 447.02M -1.18B -868.57M -6.1812

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-31-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-08-24 Initiated Stephens Equal-Weight
Sep-06-24 Initiated RBC Capital Mkts Outperform
Aug-07-24 Downgrade B. Riley Securities Buy → Neutral
Sep-11-23 Upgrade B. Riley Securities Neutral → Buy
Aug-31-22 Initiated Cowen Outperform
Jul-28-22 Initiated Barclays Overweight
Jul-06-22 Resumed Canaccord Genuity Buy
Apr-13-22 Downgrade B. Riley Securities Buy → Neutral
Apr-07-22 Resumed Cantor Fitzgerald Overweight
Feb-14-22 Initiated Morgan Stanley Equal-Weight
Dec-17-21 Initiated SVB Leerink Outperform
Dec-09-21 Initiated Needham Buy
Sep-30-21 Initiated B. Riley Securities Buy
Apr-20-21 Initiated JMP Securities Mkt Outperform
Oct-12-20 Initiated Cantor Fitzgerald Overweight
Jun-12-20 Initiated Oppenheimer Outperform
Apr-17-20 Initiated H.C. Wainwright Buy
Nov-14-19 Initiated ROTH Capital Buy
Sep-11-19 Upgrade Goldman Neutral → Buy
Jun-17-19 Initiated Canaccord Genuity Buy
Jun-17-19 Initiated Goldman Neutral
Jun-17-19 Initiated Jefferies Buy
Jun-17-19 Initiated Piper Jaffray Overweight
View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

pulisher
04:33 AM

Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

04:33 AM
pulisher
02:39 AM

Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat

02:39 AM
pulisher
Nov 02, 2025

EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView

Nov 02, 2025
pulisher
Nov 01, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat

Nov 01, 2025
pulisher
Oct 31, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa

Oct 31, 2025
pulisher
Oct 31, 2025

RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa

Oct 31, 2025
pulisher
Oct 30, 2025

Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa

Oct 30, 2025
pulisher
Oct 27, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat

Oct 27, 2025
pulisher
Oct 17, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat

Oct 17, 2025
pulisher
Oct 16, 2025

100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC - Defense World

Oct 16, 2025
pulisher
Oct 16, 2025

Global X MLP & Energy Infrastructure ETF $MLPX Holdings Boosted by Janney Montgomery Scott LLC - Defense World

Oct 16, 2025
pulisher
Oct 15, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Receives “Sell (D-)” Rating from Weiss Ratings - Defense World

Oct 15, 2025
pulisher
Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Analyzing Fractyl Health (NASDAQ:GUTS) & Plus Therapeutics (NASDAQ:PSTV) - Defense World

Oct 12, 2025
pulisher
Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Oct 12, 2025
pulisher
Oct 10, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat

Oct 10, 2025
pulisher
Oct 06, 2025

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat

Oct 06, 2025
pulisher
Oct 03, 2025

Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World

Oct 03, 2025
pulisher
Oct 02, 2025

Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat

Oct 02, 2025
pulisher
Sep 29, 2025

Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 29, 2025
pulisher
Sep 24, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat

Sep 24, 2025
pulisher
Sep 22, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat

Sep 22, 2025
pulisher
Sep 20, 2025

Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat

Sep 20, 2025
pulisher
Sep 18, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World

Sep 18, 2025
pulisher
Sep 17, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Sep 17, 2025
pulisher
Sep 15, 2025

3 Stocks To Buy Under $10 That Could Triple From Here - Barchart.com

Sep 15, 2025
pulisher
Sep 11, 2025

Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 11, 2025
pulisher
Sep 09, 2025

Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India

Sep 09, 2025
pulisher
Sep 06, 2025

Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 06, 2025
pulisher
Sep 05, 2025

Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 05, 2025
pulisher
Sep 04, 2025

Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 04, 2025
pulisher
Sep 03, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat

Sep 03, 2025
pulisher
Aug 29, 2025

Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.

Aug 29, 2025
pulisher
Aug 27, 2025

Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Aug 27, 2025
pulisher
Aug 20, 2025

Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World

Aug 20, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World

Aug 13, 2025
pulisher
Aug 08, 2025

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se

Aug 08, 2025
pulisher
Aug 01, 2025

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN

Aug 01, 2025
pulisher
Jul 31, 2025

Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com

Jul 31, 2025
pulisher
Jul 31, 2025

Should I buy Bicycle Therapeutics (BCYC) - Zacks Investment Research

Jul 31, 2025
pulisher
Jul 29, 2025

Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Jul 29, 2025
pulisher
Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025

Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.49
price down icon 0.27%
$28.64
price up icon 0.10%
$100.80
price up icon 8.05%
$104.06
price up icon 0.13%
biotechnology ONC
$312.04
price up icon 0.52%
$183.82
price down icon 3.02%
Cap:     |  Volume (24h):